127 related articles for article (PubMed ID: 25935484)
21. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
Grivas PD; Daignault S; Tagawa ST; Nanus DM; Stadler WM; Dreicer R; Kohli M; Petrylak DP; Vaughn DJ; Bylow KA; Wong SG; Sottnik JL; Keller ET; Al-Hawary M; Smith DC; Hussain M
Cancer; 2014 Mar; 120(5):692-701. PubMed ID: 24249435
[TBL] [Abstract][Full Text] [Related]
22. [Combined low-dose chemotherapy inhibiting angiogenesis and growth of Lewis lung cancinoma xenografts in mice].
Qiu M; Yi C; Hou M
Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Jul; 37(4):534-7. PubMed ID: 16909595
[TBL] [Abstract][Full Text] [Related]
23. Optimal scheduling of interleukin-12 and fractionated radiation therapy in the murine Lewis lung carcinoma.
Teicher BA; Ara G; Buxton D; Leonard J; Schaub RG
Radiat Oncol Investig; 1998; 6(2):71-80. PubMed ID: 9572683
[TBL] [Abstract][Full Text] [Related]
24. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
Huang X; Wong MK; Yi H; Watkins S; Laird AD; Wolf SF; Gorelik E
Cancer Res; 2002 Oct; 62(20):5727-35. PubMed ID: 12384531
[TBL] [Abstract][Full Text] [Related]
25. HIF-1 Dimerization Inhibitor Acriflavine Enhances Antitumor Activity of Sunitinib in Breast Cancer Model.
Yin T; He S; Shen G; Wang Y
Oncol Res; 2014; 22(3):139-45. PubMed ID: 26168132
[TBL] [Abstract][Full Text] [Related]
26. Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy.
Huber PE; Bischof M; Jenne J; Heiland S; Peschke P; Saffrich R; Gröne HJ; Debus J; Lipson KE; Abdollahi A
Cancer Res; 2005 May; 65(9):3643-55. PubMed ID: 15867359
[TBL] [Abstract][Full Text] [Related]
27. Improvement in efficacy of chemoradiotherapy by addition of an antiangiogenic agent in a murine tumor model.
McDonnell CO; Holden G; Sheridan ME; Foley D; Moriarty M; Walsh TN; Bouchier-Hayes DJ
J Surg Res; 2004 Jan; 116(1):19-23. PubMed ID: 14732345
[TBL] [Abstract][Full Text] [Related]
28. Determinants for in vivo antitumor effect of angiogenesis inhibitor SU5416 formulated in PEGylated emulsion.
Ogawara K; Abe S; Un K; Yoshizawa Y; Kimura T; Higaki K
J Pharm Sci; 2014 Aug; 103(8):2464-9. PubMed ID: 24985750
[TBL] [Abstract][Full Text] [Related]
29. DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs.
Shinohara ET; Geng L; Tan J; Chen H; Shir Y; Edwards E; Halbrook J; Kesicki EA; Kashishian A; Hallahan DE
Cancer Res; 2005 Jun; 65(12):4987-92. PubMed ID: 15958537
[TBL] [Abstract][Full Text] [Related]
30. Successful combination of sunitinib and girentuximab in two renal cell carcinoma animal models: a rationale for combination treatment of patients with advanced RCC.
Oosterwijk-Wakka JC; de Weijert MC; Franssen GM; Leenders WP; van der Laak JA; Boerman OC; Mulders PF; Oosterwijk E
Neoplasia; 2015 Feb; 17(2):215-24. PubMed ID: 25748241
[TBL] [Abstract][Full Text] [Related]
31. [The effect of VEGF antisense oligonucleotides combined with low molecular weight heparin on the growth and metastasis of mice Lewis lung cancer].
Zhang YH; Wang C; Pang BS; Zhai ZG; Weng XZ
Zhonghua Yi Xue Za Zhi; 2006 Mar; 86(11):749-52. PubMed ID: 16681948
[TBL] [Abstract][Full Text] [Related]
32. Sunitinib malate for the treatment of renal cell carcinoma.
Wood L
Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
[TBL] [Abstract][Full Text] [Related]
33. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
34. Tyrosine kinase receptor inhibitor-targeted combined chemotherapy for metastatic bladder cancer.
Wu CL; Ping SY; Yu CP; Yu DS
Kaohsiung J Med Sci; 2012 Apr; 28(4):194-203. PubMed ID: 22453067
[TBL] [Abstract][Full Text] [Related]
35. CpG oligodeoxynucleotide 1826 enhances the Lewis lung cancer response to radiotherapy in murine tumor.
Yuan S; Qiao T; Chen W
Cancer Biother Radiopharm; 2011 Apr; 26(2):203-8. PubMed ID: 21539452
[TBL] [Abstract][Full Text] [Related]
36. Combined effect of vascular-leakage-blocker Sac-1004 and antiangiogenic drug sunitinib on tumor angiogenesis.
Lee K; Agrawal V; Kim K; Kim J; Park H; Lee S; Kim YM; Suh YG; Kwon YG
Biochem Biophys Res Commun; 2014 Aug; 450(4):1320-6. PubMed ID: 25003323
[TBL] [Abstract][Full Text] [Related]
37. Contrast-enhanced Ultrasound Imaging of Antiangiogenic Tumor Therapy.
Klotz LV; Clevert DA; Scheckinger S; Strieth S; Eichhorn ME
Anticancer Res; 2015 May; 35(5):2571-6. PubMed ID: 25964532
[TBL] [Abstract][Full Text] [Related]
38. Broad spectrum receptor tyrosine kinase inhibitor, SU6668, sensitizes radiation via targeting survival pathway of vascular endothelium.
Lu B; Geng L; Musiek A; Tan J; Cao C; Donnelly E; McMahon G; Choy H; Hallahan DE
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):844-50. PubMed ID: 14967441
[TBL] [Abstract][Full Text] [Related]
39. Radiation therapy to a primary tumor accelerates metastatic growth in mice.
Camphausen K; Moses MA; Beecken WD; Khan MK; Folkman J; O'Reilly MS
Cancer Res; 2001 Mar; 61(5):2207-11. PubMed ID: 11280788
[TBL] [Abstract][Full Text] [Related]
40. [Effects of rh-endostar in combination with radiotherapy on rats with lung cancer].
Du H; Ge W; Li C; Zhao Z; Xu X; Yang F
Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):386-90. PubMed ID: 20677570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
